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Women being diagnosed with relapsing-remitting multiple sclerosis are young and many of them will eventually plan to become pregnant. Treatment with immunomodulatory drugs is often initiated in early stages of the disease. Pregnancy is an exclusion criterion in any randomized controlled trial (RCT) and at least single, sometimes even dual contraception is mandatory for female participants during RCT of immunomodulatory drugs, depending on the potential toxic risk of the investigated drug. Reproductive toxicity studies in animals can provide first clues on a potential danger for humans. 1 As most of the MS drugs were newly developed for MS, first experience on human exposure results from few (maximum 40-50, often fewer) unplanned exposed pregnancies from clinical trials. 2 Should we therefore investigate the effect of newly approved drugs on pregnancy outcomes in RCTs? The answer is no for several reasons.
RCTs aim to reduce variation in the outcome attributable to extraneous factors with the purpose to create groups that differ only randomly at the time of inclusion. In a purely scientific experiment, the reason for assigning a particular person to a specific exposure is to maximize the validity of the trial. 3 Discussions on when it is unethical to randomize patients to placebo-controlled trials include mainly the withholding of an effective treatment, if approved options are available. An RCT therefore is often an experiment to prove the effectiveness of a medical intervention and not the potential harm of an intervention. Moreover, in an experiment, those who are exposed to an experimental treatment are exposed only because the investigator has assigned the exposure to the participant. 3 This is unethical when the human safety profile of a drug is not known, which is the case for most of the new drugs at the time point of approval, and some of the drugs approved in MS are potentially dangerous in terms of teratogenicity or genotoxicity. An RCT with the aim to identify potential harm before a safety profile of the drug is defined unethical and would not get ethical approval.
Another limitation is the sample size needed, as many adverse events during pregnancy fortunately occur only rarely. Potential outcomes in a safety trial could include prevalence of major malformations, abortions, preterm birth, or number of babies small for gestational age-events with a prevalence in singledigit percentage except for spontaneous abortions. Several (up to 700) hundred exposed and non-exposed pregnancies would be necessary to demonstrate a two-fold increase in the underlying natural major malformation risk of 3%. In the unlikely event, an Institutional Review Board approved such an RCT, and it would be impossible to recruit enough voluntary participants.
A second scenario for an RCT in women with MS planning a pregnancy is to investigate the effect of the withdrawal of the MS drug prior to pregnancy. Naturally, women with MS have a significant reduction in relapse activity during pregnancy, especially during the last trimester of pregnancy. 4 Therefore, most of the pregnancies will not require specific MS medication during pregnancy. 5 However, the withdrawal of more efficient treatments with natalizumab or fingolimod might be associated with a recurrence of the prior disease activity, and the disease may even rebound severe enough to cause death. 6 The magnitude of the risk is yet unknown. Can we therefore consider a randomized control trial in this patient population to investigate the effect of the withdrawal (yes or no) or the effect of bridging therapies on the return of the disease activity or disability? On the first view, an RCT seems to be more feasible, but given that the outcome (severe rebound) is uncommon, an RCT is ethical only for drugs with a known safety profile for (entire) pregnancy exposure. Only for glatiramer acetate and interferon (IFN)-beta, enough safety data on first trimester exposure exist to perhaps meet the demands of medical ethics and treatment (primum nihil nocere). [6] [7] [8] Of note, even for glatiramer or IFNbeta, data on exposure beyond the first trimester are scarce. For newer and more effective drugs, such as natalizumab, some data (around 500 pregnancies with first trimester exposure) are published and allow some risk-benefit consideration. 6 Limited information is available on third-trimester exposure, indicating that reversible hematological abnormalities occur in the large majority of the exposed babies. 9 No information We need to conduct clinical trials of diseasemodifying therapy in pregnancy to optimize care of women with MS -No on third-trimester exposure on small molecules as fingolimod or dimethyl fumarate is available.
Would it be ethical to include women treated with natalizumab planning a pregnancy in an RCT? The answer again is no. Experiments on humans are ethically permissible only when adherence to the protocol does not conflict with the subjects' (in the case of pregnancy, two subjects) best interest, a maximum benefit with a minimum risk. Often the best interest of one of the two units (mother/embryo fetus) might be contradictory, or in the best case, there might be no theoretical concern for the baby, but not enough data are available to prove this assumption.
While it might be unethical or unfeasible for an investigator to assign a certain exposure to a person, people often willingly or unwillingly expose themselves to potential harmful factors. 3 Therefore, well-designed observational studies using modern statistical methods, for example, disease-specific registries, drug exposure registries, and data linkage of populationbased registries, are necessary to answer urging questions around the complex MS and family planning. 10 The quality of registries is in general higher than data from pharmacovigilance, with many missing data and high numbers of lost to follow-ups. Neurologists can-as the past has shown that pregnancy registries recruit very slowly-support the active participation in those registries with the inclusion of pregnant women. The earlier high-quality data are collected, the sooner a potential risk or non-risk can be communicated with the patient.
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